Odyssey Therapeutics, Inc.(ODTX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 0 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ODTX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Odyssey Therapeutics, Inc. (ODTX), a Healthcare sector company. ODTX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 0 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), Odyssey Therapeutics, Inc. reports net income of $-38.3M, free cash flow of $-41.2M. ODTX trades on the Nasdaq exchange and files with the SEC under CIK 1882782. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ODTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Odyssey Therapeutics, Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$0.00
Net Income
Q1 2026
$-38.3M
Free Cash Flow
Q1 2026
$-41.2M
AI Insight: ODTX Financial Trends
Odyssey is pre-revenue with $524M negative equity and $41M quarterly cash burn.
• Q1 2026 shows $0M revenue, operating loss of $40M, and operating cash outflow of $41M.
⚠ Negative shareholders' equity of $524M indicates cumulative losses exceed assets. Runway and path to profitability critical.
AI Insight: ODTX Ratio Trends
Odyssey Therapeutics shows insufficient data to assess trends; Q1 2026 displays negative ROA of -66.8%, indicating losses.
• Q1 2026 ROA of -66.8% reflects operating losses; insufficient historical quarters to establish trend direction.
⚠ Single quarterly snapshot limits ability to distinguish seasonal weakness from structural profitability challenges.
Get alerted when ODTX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Odyssey Therapeutics, Inc. including:
More Healthcare Companies
View all Healthcare →Put ODTX on your watchlist
Track score changes the day Odyssey Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ODTX a good stock to buy?
13F Pro's AI-powered analysis of Odyssey Therapeutics, Inc. (ODTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ODTX are available on the ODTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ODTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ODTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Odyssey Therapeutics, Inc.'s investment landscape.